Healthcare Industry News: dialysis
News Release - June 4, 2008
IDev(R) Technologies Inc. Announces Distribution Partnership with YMed Inc. for the VascuTrak 2(TM) Focal Force PTA CatheterHOUSTON--(HSMN NewsFeed)--IDev Technologies, Inc., an emerging leader in the development and marketing of minimally invasive stent systems for the treatment of peripheral vascular and non-vascular diseases, today announced an exclusive distribution agreement with YMed Inc. for sales of the VascuTrak 2TM Focal Force PTA Catheter in North America and select European markets.
The VascuTrak 2TM Focal Force PTA Catheter has been engineered for the dilatation of stenoses of the peripheral vasculature and is available in a broad range of diameter sizes and lengths to address this challenging anatomy. It is approved for use in the iliac, femoral, ilio-femoral, popliteal, infra-popliteal and renal arteries and for the treatment of obstructive lesions of native synthetic arteriovenous dialysis fistulae. The Focal Force design concentrates the forces from balloon inflation along two axial dimensions to achieve safe and effective dilatation of both soft and calcified lesions at lower balloon inflation pressures. As a result, it is believed that the incidence of barotrauma may be reduced.
Tom Tully, Chairman and CEO of IDev Technologies, Inc. stated, “The VascuTrak 2TM Focal Force PTA Catheter is a highly innovative complement to our existing product line and is consistent with our long-term clinical initiatives in peripheral vascular disease.”
YMed Inc. President and CEO Yoav Shaked commented, “YMed Inc. is committed to the development of novel technologies for vascular intervention providing less invasive therapies for a broad range of circulatory diseases. The partnership forged today with IDev Technologies, Inc. is a milestone toward the vision of commercializing our intellectual patent portfolio and products into global health care solutions.”
About IDev Technologies
IDev Technologies, Inc., located in Houston, Texas, is an innovator and developer of next generation medical devices for use in the interventional radiology, vascular surgery and cardiology device marketplace. Its current portfolio contains over thirty technologies exclusively licensed from the M.D. Anderson Cancer Center, representing over a $5.0 billion dollar market opportunity worldwide.
YMed, Inc. is a privately held corporation established in 2004. The company was founded and is managed by a highly experienced, multinational team of medical, engineering and business professionals from within the cardio and peripheral vascular industry. This team develops, manufactures and markets innovative products for vascular intervention providing less invasive therapies for a broad range of circulatory diseases.
Source: IDev Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.